Learn About CACH Syndrome

What is the definition of CACH Syndrome?

Leukoencephalopathy with vanishing white matter is a progressive disorder that mainly affects the brain and spinal cord (central nervous system). This disorder causes deterioration of the central nervous system's white matter, which consists of nerve fibers covered by myelin. Myelin is the fatty substance that insulates and protects nerves.

What are the causes of CACH Syndrome?

Mutations in the EIF2B1, EIF2B2, EIF2B3, EIF2B4, and EIF2B5 genes cause leukoencephalopathy with vanishing white matter.

How prevalent is CACH Syndrome?

The prevalence of leukoencephalopathy with vanishing white matter is unknown. Although it is a rare disorder, it is believed to be one of the most common inherited diseases that affect the white matter.

Is CACH Syndrome an inherited disorder?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top CACH Syndrome Local Doctors?
Gerald V. Raymond
Elite in CACH Syndrome
Pediatrics | Medical Genetics
Elite in CACH Syndrome
Pediatrics | Medical Genetics

Rubenstein Child Health Building

Baltimore, MD 
Languages Spoken:
English

Dr. Gerald Raymond is a clinical geneticist and neurologist at Johns Hopkins where he is also a professor of genetic medicine and neurology. He obtained his MD at the University of Connecticut and was trained in Pediatrics at Johns Hopkins Hospital and Neurology at the Mass. General Hospital. He received additional training in developmental neuropathology at the Universite Catholique de Louvain in Belgium and clinical genetics at the Harvard Program. Dr. Raymond’s research has been at the overlap of genetics and neurology with specific focus on peroxisomal disorders including adrenoleukodystrophy. He has been actively involved in newborn screening for ALD and in developing clinical follow-up programs. He has extensive experience in clinical management of neurogenetic issues including peroxisomal and lysosomal disorders. He presently serves as the Director of the Lysosomal Storage Disease program in the department of Genetic Medicine. Dr. Raymond is rated as an Elite provider by MediFind in the treatment of CACH Syndrome. His top areas of expertise are Adrenoleukodystrophy (ALD), CACH Syndrome, Zellweger Syndrome, and Leukodystrophy.

Igor J. Koralnik
Elite in CACH Syndrome
Elite in CACH Syndrome

Regenstein Center For Neurological Care - Lavin Family Pavilion

259 E Erie St, Ste 1900, 
Chicago, IL 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Igor Koralnik is a Neurologist in Chicago, Illinois. Dr. Koralnik is rated as an Elite provider by MediFind in the treatment of CACH Syndrome. His top areas of expertise are Progressive Multifocal Leukoencephalopathy, CACH Syndrome, Encephalitis, Thrombectomy, and Endovascular Embolization. Dr. Koralnik is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in CACH Syndrome
Pediatric Neurology
Elite in CACH Syndrome
Pediatric Neurology

Primary Children's Neurology Clinic - Salt Lake City

81 North Mario Capecchi Drive, 
Salt Lake City, UT 
Experience:
28+ years
Languages Spoken:
English, German
Accepting New Patients
Offers Telehealth

Joshua Bonkowsky is a Pediatric Neurologist in Salt Lake City, Utah. Dr. Bonkowsky has been practicing medicine for over 28 years and is rated as an Elite provider by MediFind in the treatment of CACH Syndrome. His top areas of expertise are CACH Syndrome, Adrenoleukodystrophy (ALD), Leukodystrophy, Krabbe Disease, and Gastrostomy. Dr. Bonkowsky is currently accepting new patients.

What are the latest CACH Syndrome Clinical Trials?
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation

Summary: The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Who are the sources who wrote this article ?

Published Date: May 01, 2013
Published By: National Institutes of Health